Coordinator: F.Montemurro, MD


Clinicians and clinical trial specialists collaborate with basic scientists with detailed knowledge of oncogene signaling pathways, genetics and tumor biology in designing biomarker-driven trials that test specific hypotheses about mechanisms of resistance. INCO implements carefully selected, well-focused research programs aimed at generating hypothesis-driven clinical trials within reasonable time-frames. To improve current therapeutic options, INCO organizes a structure for meaningful interactions between scientists, the medical oncology community and the pharma industry as a provider of potential new drugs. Moreover, it promotes a “clinical research culture” among clinicians, scientists and patient advocacy groups. This initiative, in turn, facilitates patient referral into high-impact clinical trials and the achievement of recruitment objectives and reduces the time required to launch clinical trials.